Skip to content

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

Clinical and Molecular Outcomes of Dabrafenib/Trametinib-Based Combination Therapy in Acquired BRAF V600E-Mutant NSCLC Following Tyrosine Kinase Inhibitor Resistance: A Preliminary Single-Center Retrospective Study.

Dabrafenib/trametinib-based combination therapy may show clinical activity in selected patients with acquired BRAF V600E-mutant NSCLC after TKI resistance, however, the extremely small sample size, heterogeneous outcomes, and clinically significant toxicities preclude definitive conclusions regarding efficacy or safety...

Dan Xu, Fang Hao, Xia Liu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.